ArticleFrontiers in oncology2025
A novel approach to enhance beta-sitosterol bioavailability isolated from
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Lung cancer remains a significant health challenge, often resulting in a poor prognosis due to the limited availability of effective targeted therapies. Beta-sitosterol (BS), extracted from Methods: BS was isolated using column chromatography, with high-performance liquid chromatography (HPLC) confirming its purity. The ionic crosslinking method with tripolyphosphate (TPP) was employed to formulate chitosan-based nano beta-sitosterol (BSC). The characterization of the nanoparticles was performed using field emission scanning electron microscopy (FE-SEM), dynamic light scattering (DLS), X-ray diffraction (XRD), and Fourier transform infrared spectroscopy (FTIR). Cell-based assays, including 4',6-diamidino-2-phenylindole (DAPI) staining, colony formation, apoptosis, and cell cycle analysis, were conducted to assess the effects of nano β-sitosterol compared to its pure form on A549 lung cancer cell lines. Results: β-Sitosterol (0.6% w/w) was isolated from Discussion: Chitosan-encapsulated nano β-sitosterol demonstrated enhanced solubility, sustained release, and improved therapeutic efficacy against lung cancer, highlighting its potential as a promising delivery system for lung cancer with improved therapeutic outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.